FIDELIS PHARMACEUTICALS LLC – Trademark Portfolio
Entity Type: 16
FIDELIS PHARMACEUTICALS LLC holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include ETHIQA XR, FIDELIS PHARMACEUTICALS, and ETHIQA XR (BUPRENORPHINE EXTENDED-RELEASE INJECTABLE SUSPENSION) 1.3 MG/ML. The owner is based in North Brunswick, NJ.
Suite B113
675 US Highway One
North Brunswick, NJ 08902
Showing of trademarks Trademarks
Trademark Classifications
FIDELIS PHARMACEUTICALS LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does FIDELIS PHARMACEUTICALS LLC have?
FIDELIS PHARMACEUTICALS LLC has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.
What trademark classes does FIDELIS PHARMACEUTICALS LLC file in?
FIDELIS PHARMACEUTICALS LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are FIDELIS PHARMACEUTICALS LLC's most well-known trademarks?
FIDELIS PHARMACEUTICALS LLC's registered trademark portfolio includes well-known marks such as ETHIQA XR, FIDELIS PHARMACEUTICALS, and ETHIQA XR (BUPRENORPHINE EXTENDED-RELEASE INJECTABLE SUSPENSION) 1.3 MG/ML. These are among 3 currently registered trademarks in the portfolio.
What is FIDELIS PHARMACEUTICALS LLC's trademark registration success rate?
FIDELIS PHARMACEUTICALS LLC has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.